August 19, 2019 — The nature of liver disease is shifting in the U.S. Over the last three decades, hepatitis C has dropped by nearly half. But over that same time, we’ve seen more liver disease due to obesity and diabetes. In fact, NAFLD (non-alcoholic fatty liver disease) has grown in almost perfect synchrony with obesity and type 2 […]
April 12, 2019 — It’s been a long road for Intercept Pharmaceuticals to develop an important advance for treating NASH (non-alcoholic steatohepatitis). Five years ago this little startup company shocked the world when a monitoring board stopped a placebo-controlled study because their drug (obeticholic acid or OCA) had worked so well. A final round of 64 liver biopsies were […]
December 24, 2018 — In all of the talk about the complications of obesity, much of the focus is on type 2 diabetes. But the health threat may be just as big – or even bigger – from non-alcoholic fatty liver disease (NAFLD). And it can start at an early age. A big part of the problem is that it often goes […]
November 28, 2017 — When most people think about obesity, the only complication they think of is type 2 diabetes. Quite a few people (but not a majority) think of heart disease. But few people think about liver disease. Unfortunately, Nonalcoholic steatohepatitis (NASH) can be one of the most serious complications a person with obesity will face. NASH is […]
May 21, 2015 — People living with obesity are finally beginning to see more options for obesity care and, in part, they can thank competition to innovate in diabetes care for some of this progress. A particularly visible example of this is liraglutide, which has been available for treating type 2 diabetes since 2009. After six years of use […]
